Ultrasound Report Analysis - Mr. Gopal Singh Dangi, 85M

Key Findings Summary

Prognosis Assessment

1. The Bladder Lesion - Most Concerning Finding

• Size ~4.7 x 2.9 cm - large tumor
• Irregular margins - suggests invasive behavior rather than superficial papillary disease
• Involvement of the left VUJ - the tumor is obstructing the left ureter where it enters the bladder
• Causing hydroureteronephrosis - upstream ureteric and kidney pelvic dilatation due to obstruction at the VUJ. As noted in Grainger & Allison's Diagnostic Radiology: "Identification of preoperative hydronephrosis and hydroureter is associated with more aggressive disease"
• Diffuse bladder wall thickening - indicates the disease may be more widespread within the bladder

2. Staging and Survival Data

"Clinical outcomes correlate closely with staging: 5-year overall survival rates of 70-90% for disease confined to the bladder (Stage I-II), 39-50% for disease that penetrates through the bladder or has spread to regional lymph nodes (Stage III), and only 8% for disease extending to metastatic sites (Stage IV)."

• This patient's lesion, based on ultrasound alone, likely falls into Stage II-III territory at minimum
• VUJ involvement with hydronephrosis worsens the staging picture
• No lymphadenopathy or free fluid on this scan is a relatively reassuring sign (no obvious nodal/peritoneal spread seen)

3. Age Factor - 85 Years

• Standard curative treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy (surgical removal of the bladder) - this carries very high surgical risk in an 85-year-old
• Bladder-sparing trimodal therapy (TURBT + chemotherapy + radiation) is an alternative, but requires fitness for chemotherapy and concurrent radiation
• Active surveillance or palliative management may be more appropriate if the patient has significant comorbidities

4. Additional Findings (Not Life-Threatening in Isolation)

• Prostatomegaly (~50 g): BPH (benign prostate enlargement). The protruding median lobe may contribute to bladder outlet symptoms but is unlikely to be malignant based on this scan alone. PSA testing would clarify.
• Simple left renal cysts: Benign; no action needed.
• Cholelithiasis/chronic cholecystitis: A separate finding; likely asymptomatic. No acute cholecystitis (no pericholecystic fluid, normal wall thickness).

Summary and What Needs to Happen Next

This is a suspected bladder cancer with locally advanced features. Prognosis cannot be precisely stated until histopathology confirms the diagnosis and CT staging is done.

Disclaimer: This analysis is for information only and is not a substitute for clinical consultation. The radiologist has appropriately recommended cystoscopy and biopsy - these are essential before any prognosis can be formally given.

CT Scan: What It Can and Cannot Tell You

Short Answer

What CT Does Well

• Detecting lymph node enlargement (nodes >1 cm are suspicious for metastasis) - with ~86% accuracy for lymph node spread (Campbell-Walsh Urology)
• Finding liver, lung, or distant metastases
• Assessing hydronephrosis extent (already suggested on ultrasound)
• Showing the upper urinary tracts (renal pelvis, ureters) to rule out upper tract tumour - important since urothelial cancer can be multifocal
• Detecting perivesical fat invasion (T3b stage) when the outer bladder margin is irregular - ~72% accuracy

What CT Cannot Do Well

"Reported CT staging accuracy has generally been low, in some studies ranging from 40% to 60%, with both overstaging and understaging being frequent problems." - Grainger & Allison

"CT was correct in 63%, overstaged in 31%, and understaged in 6%." - Campbell-Walsh Urology

• Distinguish between non-muscle-invasive (T1) and muscle-invasive (T2) disease - this distinction is critical for treatment decisions
• Determine depth of muscle invasion (T2a vs T2b)
• Detect small-volume pelvic lymph node metastases
• Tell you the histological type (urothelial vs. squamous vs. adenocarcinoma) or grade (low vs. high) of the tumour

How CT Compares to Other Tools

For This Patient (Mr. Gopal Singh Dangi, 85M)

1. CT chest/abdomen/pelvis with contrast (CTU) - do this first to assess for nodal disease and metastases before any invasive procedure. This will critically determine if the disease has already spread beyond the pelvis.
   • Note: His left hydroureteronephrosis may already be impairing renal function - check creatinine before giving IV contrast. If eGFR is low, MRI with gadolinium contrast is the alternative.
2. Cystoscopy + biopsy - this is non-negotiable to confirm it is cancer, determine the type, and assess the tumour inside the bladder directly. The radiologist has specifically recommended this.
3. MRI pelvis - if there is uncertainty after CT about local invasion depth, or if planning bladder-sparing treatment, MRI gives more accurate local staging.

What CT Adds Over Ultrasound

• Detects lymph node spread (~86% accuracy) and distant metastases (liver, lungs, bones)
• Shows perivesical fat invasion (T3b) when the outer bladder margin is irregular
• Evaluates the full urinary tract (CT urography) - rules out upper tract tumours in the kidney/ureter
• Quantifies the degree of hydronephrosis more precisely

What CT Still Cannot Do

• Cannot confirm cancer - a mass on CT could still be a blood clot, inflammatory lesion, or benign tumour
• Cannot determine histological type or grade (urothelial, squamous, adenocarcinoma; low vs. high grade) - this requires tissue
• Local T-staging accuracy is only 40-63% on CT - it frequently overstages or understages
• Cannot distinguish T1 from T2 (non-muscle-invasive vs. muscle-invasive) - this is the single most important treatment decision

The Definitive Hierarchy

Safety of Biopsy (TURBT) in This Patient

The Good News: TURBT Is a Minimally Invasive Procedure

Specific Risks in an 85-Year-Old

1. Anaesthesia Risk (Most Significant Concern)

• Spinal anaesthesia (preferred in elderly - avoids the risks of general anaesthesia, keeps the patient awake, allows monitoring)
• General anaesthesia (higher risk in very elderly - cardiovascular, respiratory, delirium)

2. Bleeding (Haematuria)

• The tumour is 4.7 x 2.9 cm - a large, likely vascular lesion
• Significant post-procedure haematuria is possible
• May require bladder irrigation or, rarely, transfusion
• Bleeding risk is higher in patients on aspirin, warfarin, or clopidogrel - these would need to be reviewed before the procedure

3. Bladder Perforation

• Occurs in a small minority of TURBT cases
• Specifically heightened when the lateral wall is involved, due to the obturator nerve reflex - electrocautery can trigger sudden hip adduction and inadvertent deep resection (Campbell-Walsh Urology)
• This patient's tumour is on the posterior wall, which is actually a safer location than the lateral wall in terms of obturator reflex risk
• Perforation risk also increases with deep, muscle-invasive tumours

4. Urinary Tract Infection / Urosepsis

• The patient already has hydronephrosis (obstructed left kidney) and an enlarged prostate
• This creates a higher baseline bacterial colonisation risk
• Prophylactic antibiotics before the procedure are standard and essential here
• Urosepsis, while uncommon, is more dangerous in an 85-year-old

5. Obturator Nerve Stimulation

• As above, lateral bladder tumours carry this risk more than posterior wall tumours
• Can be managed with muscle relaxants under general anaesthesia, or careful technique

Risk vs. Benefit Assessment for This Patient

What Needs to Be Assessed Before Proceeding

1. Cardiopulmonary fitness - ECG, chest X-ray, basic bloods including renal function
2. Current medications - especially blood thinners (need to be stopped beforehand)
3. Renal function - already at risk given left hydronephrosis
4. Patient's wishes and goals of care - at 85, this conversation is essential
5. Anaesthetics pre-assessment - an anaesthetist should evaluate him before any procedure

Bottom Line

Safety of Surgical Tumour Removal at Age 85

Option 1: TURBT (Endoscopic Removal Through the Urethra)

• Minimally invasive - no incisions, done through the urethra
• Generally feasible and safe even at 85 under spinal anaesthesia
• Can remove the visible tumour and provide tissue diagnosis simultaneously
• However, for a large, muscle-invasive tumour like this (4.7 cm, involving the VUJ with hydronephrosis), TURBT alone is not a curative procedure - it cannot achieve clear margins in deeply invasive disease
• It is used as palliation, symptom control (bleeding, obstruction), and staging

Option 2: Radical Cystectomy (Complete Surgical Removal of the Bladder)

Mortality Risk by Age - Hard Numbers

• Median blood loss 500-1000 mL, transfusion rate 21.8%
• 30-day mortality in patients over 65 years: 5.2% (Surveillance, Epidemiology and End Results-Medicare database of 5207 patients)

• 90-day high-grade complication rate: 13% in the 80+ group
• 90-day non-cancer mortality: 2.3% (comparable to under-80s at 1.8%)
• But 12-month other-cause mortality was 8% in the 80+ group vs 3% in under-80s

"Robot-assisted radical cystectomy is a viable and safe procedure for carefully selected elderly patients when performed in high-volume specialized centres" - the key phrase being carefully selected.

What Makes This Patient Particularly High Risk

Specific Surgical Complications to Know

• Haemorrhage requiring transfusion (~22%)
• Postoperative ileus (bowel stops working temporarily)
• Intestinal anastomotic leak (serious, can be life-threatening)
• Urinary extravasation (urine leakage at anastomosis)
• Deep vein thrombosis / pulmonary embolism
• Urosepsis
• Cardiac events (heart attack, arrhythmia)
• Delirium - very common post-operatively in the elderly, and can be the first sign of serious complications
• Acute kidney injury - risk from blood pressure control during surgery (mean arterial pressure below 55-65 mmHg linked to AKI and stroke)

The Honest Risk-Benefit Picture for This Patient

What the Evidence Actually Recommends

1. Good functional status / ECOG performance status 0-1 (can perform daily activities independently)
2. Absence of major cardiac, respiratory, or renal comorbidities
3. Patient understanding and willingness to accept a permanent urostomy
4. No distant metastases on CT staging
5. Adequate renal function (his hydroureteronephrosis raises concern here)

Alternatives Worth Knowing About

• Palliative TURBT - control bleeding/obstruction, not curative
• Radiotherapy alone or with chemotherapy (trimodal therapy) - bladder-sparing but excluded if hydronephrosis is present (as already noted)
• Palliative systemic chemotherapy or immunotherapy - if metastatic or unresectable
• Best supportive/palliative care - entirely appropriate if the patient's goals prioritise quality of life over cure